Last Updated: November 13, 2026

Amta Company Profile

« Back to Dashboard

What is the competitive landscape for AMTA

AMTA has five approved drugs.

Summary for Amta

US Patents:	0
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Amta

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amta	DILTIAZEM HYDROCHLORIDE	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216439-001	Mar 7, 2023	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Amta	DILTIAZEM HYDROCHLORIDE	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216439-002	Mar 7, 2023	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Amta	TOPIRAMATE	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	218695-005	Dec 3, 2024	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
Amta	TOPIRAMATE	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	218695-004	Dec 3, 2024	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
Amta	MESALAMINE	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	217533-001	Jun 6, 2023	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Amta

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.